Date:25 April, 2014

Glassia, improved infusion rate

Kamada Ltd, a plasma-derived protein therapeutics company focused on orphan indications, announces a significantly improved infusion rate for Glassia(R) (Alpha1-Proteinase Inhibitor -Human); this improvement was recently approved by the US Food and Drug Administration (FDA). Glassia, which is marketed in the U.S. through a strategic partnership by Baxter International Inc., is the first and only ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) approved by the FDA and is indicated as a chronic augmentation and maintenance therapy in adults with alpha-1 antitrypsin deficiency.

In 2012 Kamada, announced that it had entered into an exclusive distribution agreement with Chiesi Farmaceutici S.p.A, a fully integrated European Pharmaceutical company focused on respiratory disease and special care products, for the distribution of its inhaled alpha-1 antitrypsin.  The agreement covered Europe, Turkey and former CIS countries.